While both drugs lead to significant weight reduction, Retatrutides unique mechanism targets specific high-risk metabolic conditions more aggressively: This dual vs
GonzlezSMoreno-DelgadoDMorenoEPrez-CapoteKFrancoRMallolJet al
Across the SUSTAIN program, the primary and confirmatory secondary endpoints for most trials were change from baseline in HbA 1c and body weight, respectively, to the end of treatment (30, 40, 52, or 56 weeks) ( 1c and body weight, respectively ( 1c Set al
One review of rituximab trials showed that 72% of patients treated with the drug achieved significant clinical improvements (Cervinek 2012)
After optimizing the analysis conditions, a Diol column (100 3 mm i.d., 1.7 m) was selected as the stationary phase (Antonelli et al., 2022)